NCT07126652Not yet recruiting
Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 17 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Until now, the adjuvanted influenza-related studies focused mainly on people at older ages. However, the data on immunocompromised people, who might have suboptimal serological responses when receiving nonadjuvanted vaccines, is scarce. In this study, we aim to compare the immunogenicity and safety to adjuvanted versus nonadjuvanted seasonal influenza vaccines among people with HIV.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 11 Aug 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- HIV
- NCT number
- NCT07126652
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 1 Oct 2025 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Confirmed serious adverse effect owing to any type of inluenza vaccine
- Have recieved influenza vaccine of 2025-2026 season
Other
- severe coagulopathy
Who the study is looking for
- People with HIV aged \> 50 years
- Latest HIV RNA load tested less than 330 IU/mL
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.